Monitor Denali's upcoming Phase 1/2 data readout for DNL593 by end of 2026, which will be critical for validating the program's potential without Takeda's backing and determining future partnership or funding needs.
Price Chart
Executive Summary
Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement to co-develop and co-commercialize DNL593 for frontotemporal dementia, citing strategic reasons unrelated to efficacy or safety. Denali will regain full rights to the program and continue its clinical development independently, with Phase 1/2 data expected by end of 2026.
Key Facts
- Takeda terminated the 2018 collaboration agreement for DNL593 (PTV:PGRN) for FTD-GRN due to strategic considerations, not efficacy or safety issues
- All rights to DNL593 will revert to Denali 60 days after the April 3, 2026 notice
- Denali will have no further financial obligations to Takeda post-termination
- Denali plans to continue clinical development of DNL593 independently
- Data from the ongoing Phase 1/2 study in FTD-GRN patients is expected by end of 2026
Financial Impact
Loss of Takeda's financial support for DNL593 development; Denali assumes full funding responsibility
Risk Factors
- Increased financial burden on Denali to fund DNL593 development independently
- Loss of Takeda's commercialization expertise and resources for a potential future launch
- Clinical data expected in late 2026 may face delays or fail to meet efficacy endpoints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001714899-26-000042 |
| Exhibit: ex9912026pressrelease4326.htm | 0001714899-26-000042 |
| Document: 0001714899-26-000042-index-headers.html | 0001714899-26-000042 |
| Document: 0001714899-26-000042-index.html | 0001714899-26-000042 |
| Document: 0001714899-26-000042.txt | 0001714899-26-000042 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $21.57 $20.06 | ▼ −7.00% | ▼ −6.34% | $20.00 (−7.28%) |
Sep 4, 2026 28d ago | Insider Cluster | $22.08 $20.38 | ▼ −7.70% | ▼ −6.58% | $20.00 (−9.42%) |
Aug 6, 2026 8w ago | 8-K | $24.83 $24.40 | ▼ −1.73% | ▼ −2.13% | $20.00 (−19.45%) |
Jul 27, 2026 9w ago | Press Release | $24.05 $23.15 | ▲ +3.74% | ▲ +6.01% | $20.00 (+16.84%) |
Jun 18, 2026 15w ago | 8-K | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 18, 2026 15w ago | Press Release | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.02 $23.49 | ▲ +11.75% | ▲ +11.32% | $20.00 (−4.85%) |
May 21, 2026 19w ago | Press Release | $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $20.00 (−7.30%) |
May 7, 2026 21w ago | Press Release | $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $20.00 (+1.94%) |
Apr 3, 2026 26w ago | 8-K | $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $20.00 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access